About enliven therapeutics inc - ELVN
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.
ELVN At a Glance
Enliven Therapeutics, Inc.
6200 Lookout Road
Boulder, Colorado 80301
| Phone | 1-720-647-8519 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -89,024,000.00 | |
| Sector | Health Technology | Employees | 62 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
ELVN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3.554 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -7.153 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
ELVN Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,435,870.968 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ELVN Liquidity
| Current Ratio | 19.989 |
| Quick Ratio | 19.989 |
| Cash Ratio | 19.698 |
ELVN Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -29.792 |
| Return on Equity | -32.037 |
| Return on Total Capital | -28.732 |
| Return on Invested Capital | -32.037 |
ELVN Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |